Neonatal Anthropometrics and Obesity Treatment Response in Children and Adolescents

Ulrik Lausten-Thomsen1, Morten Asp Vonsild Lund2, Sara Elizabeth Stinson3

  • 1Department of Neonatology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

The Journal of Pediatrics
|November 14, 2021
PubMed

Insights

Neonatal measurements correlate with initial obesity severity in children but do not predict treatment response. Therefore, using neonatal anthropometrics to tailor childhood obesity treatment is not recommended.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Public Health

Background:

  • Childhood obesity is a growing public health concern.
  • Early life factors, including in utero growth, may influence obesity development and treatment outcomes.
  • Neonatal anthropometrics offer a potential window into early growth patterns.

Purpose of the Study:

  • To explore the association between neonatal anthropometric measures and childhood obesity treatment response.
  • To evaluate if neonatal measurements can stratify children for obesity treatment effectiveness.

Main Methods:

  • Retrospective analysis of 2474 children and adolescents with obesity.
  • Utilized national electronic registers for neonatal data (birth weight, length, gestational age).
  • Prospectively tracked treatment response over a mean of 1.27 years.

Main Results:

  • Neonatal anthropometrics (birth weight, length, large for gestational age) were linked to higher obesity severity at treatment start.
  • No significant association was found between neonatal measures and the degree of treatment response.
  • Children achieved a mean reduction of -0.32 in BMI SDS after treatment.

Conclusions:

  • While neonatal anthropometrics reflect initial obesity burden, they do not predict response to multidisciplinary obesity treatment.
  • Individualizing childhood obesity treatment based on neonatal anthropometry is not supported by these findings.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
705
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
16
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
16
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
24
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
19
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
21